Drug reduces size of some lung cancer tumors, relapse rate after surgery
Share

IMAGE: The research teams discovered new infiltration of immune cells into the lung cancer after nivolumab, an anti-PD-1 drug, was administered. view more 

view more 

Credit: Johns Hopkins Kimmel Cancer Center

A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients.

The research teams at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Johns Hopkins Sidney Kimmel Cancer Center and the Memorial Sloan-Kettering Cancer Center wanted to find out if providing nivolumab, an anti-PD-1 drug, would stimulate anti-tumor immunity in patients with non-small-cell lung cancer (NSCLC) who were going to have their tumors surgically removed.

Johns Hopkins Bloomberg~Kimmel Institute for Cancer ImmunotherapyJohns Hopkins Sidney Kimmel Cancer CenterMemorial Sloan-Kettering Cancer Center

The study showed after 21 patients received two doses of nivolumab before surgery, there was a major pathologic response in 45 percent of the removed tumors and no delays in any of the planned surgeries. In addition, neoantigen-specific T-cell clones were stimulated by the drug and present in the blood and tumor but disappeared from the body after the tumor was removed.

The study

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD